ISAR Research Updates
Research topics prioritised by the ISAR Steering Committee for 2020:
Define Responders and Non-Responders to Biologics and Describe Their Characteristics Overall and Per Biologic (BEAM)
Describe the Clinical Outcome Before and After Biologic Treatment by Biologic Class, by Individual Biologic, and by Subgroups of Baseline Characteristics (LUMINANT)
Previously, ISAR Steering Committee (ISC) members voted for 1 fully funded project and 4 academic projects. Henceforth from 2019, the ISC members will vote for 2 fully funded projects.
Research topics prioritised by the ISC members for the year 2019:
Impact of Co-Morbidity in Severe Asthma (PRISM)
Comparative effectiveness across severe asthma biologic classes (Anti-IL5 vs Anti lgE) in patients eligible for both modalities (FIRE)
The following research topics were prioritized during the ISC Closed session for 2019 and are open to researchers to join and lead. Submit your interest through our website or contact your country lead for further details.
|What is the OCS landscape: annual consumption, prevalence, outcomes and side-effects of long-term OCS users?||Read More|
|Describe the characteristics of severe asthma patients with inflammatory phenotypes and FEV1 <40%?||Read More|
|What is the characterization of health disparities across countries?||Read More|
|What are the criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma?||Read More|
Research topic prioritized by the ISAR steering committee for the second year 2018:
The Characterization and Comparison of Eosinophilic and Non-Eosinophilic Phenotypes of Severe Asthma
– To describe and compare the demographic and clinical features of the eosinophilic versus non-eosinophilic severe asthma phenotypes and to investigate the unique clusters of asthma phenotypes in the ISAR.
Group characterization and feasibility numbers were presented at the REG summit 2019 during the ISAR Research Collaborator Meeting.
Hidden Severe Asthma in Primary Care*
Biologics in Severe Asthma: Utilization Patterns, Causes for Discontinuation and Switching and Adverse Outcomes*
BRISAR: Biomarker Relatability in ISAR
The Role of Exacerbations on Lung Function Trajectory*
Identify Predictors (e.g. biomarkers) of Response to Biologics
Hidden Chronic Asthma within the COPD/ACO Population
Onset of Asthma in Severe Asthma patients
Relationship between Socioeconomic Status and Asthma Outcome
*Note: Funded Studies
Research topic prioritized by the ISAR steering committee for the inaugural year 2017:
Demographic and Clinical Characteristics of Severe Asthma Patients Worldwide
– To describe and compare the demographic and clinical characteristics of the severe asthma population globally
– Demographic Distribution, Medication, Comorbidities, Asthma Control, Eosinophils, and IgE counts, Lung Function, Healthcare Resource Utilization, etc.
4,990 patients from five countries have contributed to this first research project of ISAR.